COLL vs LLY
As of Sep 20, 2026, Collegium Pharmaceutical (COLL) scores 2.9/10 and ELI LILLY (LLY) 7.2/10 on AlphaStocks' five-model composite, so LLY scores higher. LLY trades 76% above its model fair value.
COLL
COLLEGIUM PHARMACEUTICAL, INC
2.9
Avoid
$22.79
LLY
ELI LILLY & Co
7.2
Consider Buy
$1,152.46
COLL vs LLY: Which is the Better Investment?
COLLEGIUM PHARMACEUTICAL, INC (COLL) scores 2.9/10 while ELI LILLY & Co (LLY) scores 7.2/10 on AlphaStocks' composite model. ELI LILLY & Co has the higher composite rating of Consider Buy. On a P/E basis, COLLEGIUM PHARMACEUTICAL, INC trades at 14.4x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | COLL | LLY |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 2.9/10 | 7.2/10▲ |
| Rating | Avoid | Consider Buy▲ |
| Price | $22.79 | $1,152.46 |
| P/E Ratio | 14.4▲ | 50.2 |
| ROE | 10.2% | 82.0%▲ |
| Market Cap | $913.1M | $1.0T |
| Fair Value | — | $656.48 |
| Dividend Yield | — | 0.5% |
| Sector Rank | #156 of 168 | #11 of 168▲ |
| Model Verdicts | ||
| Piotroski | Attractive | Strong▲ |
| Buffett | Neutral | Strong▲ |
| Graham | Caution | Caution |
| Lynch | Neutral | Neutral |
| Greenblatt | Strong▲ | Caution |
Related comparisons
COLL vs LLY: Which Stock Scores Higher?
COLLEGIUM PHARMACEUTICAL, INC (COLL) and ELI LILLY & Co (LLY) are both in the Health Care sector. LLY currently leads with a composite score of 7.2/10 (Consider Buy) compared to COLL's 2.9/10 (Avoid).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer